ANMAT Revokes Marketing Authorizations for Inmunolab S.A.: Analyzing the Implications
Overview of ANMAT Disposition 338/2026 On February 6, 2026, the National Administration of Drugs, Food and Medical Technology (ANMAT) issued Disposition 338/2026, a critical regulatory decision that has significant implications for public health and safety in Argentina. This ruling specifically revokes the marketing authorizations for the products of Inmunolab S.A., a manufacturer operating within pharmaceutical … Read more